Bradley L. Campbell is the President and Chief Executive Officer of Amicus Therapeutics (NASDAQ: FOLD) and is also a member of the Board of Directors. He has over 20 years of experience in the Orphan Drug industry.

Bradley joined Amicus in 2006 and has held various senior and executive roles throughout his tenure at the company, including Vice President of Business Planning, Senior Vice President of Business Operations, Chief Business Officer, and most recently serving as President and Chief Operating Officer from 2015 to 2022. Mr. Campbell built and led the global organization responsible for the commercialization of Galafold® and among his various roles has overseen the Technical Operations, Patient Advocacy, Market Access, Program Management, Clinical Operations, and Regulatory Affairs functions.

Bradley currently serves on a number of Boards including Gennao Bio, the Alliance for Regenerative Medicine (ARM), and the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. He previously served on the Board of Progenics Pharmaceuticals (NASDAQ: PGNX) from 2016 until its successful acquisition by Lantheus Holdings in 2020, as well as ARYA Sciences Acquisition Corp III, a healthcare focused Special Purpose Acquisition Vehicle.

Prior to Amicus, Bradley spent time in various commercial and business development roles at Genzyme and Bristol-Myers Squibb and as a strategy consultant for Marakon Associates. He received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.